MONROVIA, Calif., Dec. 3, 2013 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR) today announced the pricing of its initial public offering of 12,730,000 shares of its common stock at a public offering price of $5.50 per share. In addition, Xencor has granted the underwriters a 30-day option to purchase up to an additional 1,909,500 shares of common stock at the same price to cover over-allotments, if any. All shares of the common stock in this offering are being sold by Xencor, Inc. The shares are scheduled to begin trading on the NASDAQ Global Market on December 3, 2013 under the symbol "XNCR." The offering is expected to close on December 6, 2013, subject to customary closing conditions.
Credit Suisse Securities (USA) LLC and Leerink Swann LLC are acting as joint book-running managers of the offering. Wedbush PacGrow Life Sciences is acting as a co-manager for the offering.
A registration statement relating to the securities being sold in this offering was declared effective by the U.S. Securities and Exchange Commission on December 2, 2013. This offering is being made only by means of a prospectus forming part of the effective registration statement. A copy of the prospectus can be obtained from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, by calling toll-free (800) 221-1037, or by emailing email@example.com; or Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, or by email at Syndicate@Leerink.com, or by phone at (800) 808-7525.
This news release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Xencor, Inc.
Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Currently, five antibodies are in clinical development internally and with partners that have been engineered with Xencor's XmAb technology. Xencor's internally-discovered programs include XmAb5871, in Phase 1b/2a clinical trials for the treatment of Rheumatoid arthritis and lupus, XmAb7195 in preclinical development for the treatment of asthma, and XmAb5574/MOR208 which has been licensed to Morphosys AG and is in Phase 2 clinical trials for the treatment of acute lymphoblastic leukemia and non-Hodgkin lymphoma. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. Xencor partners include Amgen, Merck, Janssen R&D LLC and Boehringer Ingelheim.
Canale Communications for Xencor
SOURCE Xencor, Inc.